- Home
- IINN vs EQ Comparison
IINN vs EQ Comparison
Compare IINN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- EQ
- Stock Information
- Founded
- IINN 2018
- EQ 2017
- Country
- IINN Israel
- EQ United States
- Employees
- IINN N/A
- EQ N/A
- Industry
- IINN Medical/Dental Instruments
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- EQ Health Care
- Exchange
- IINN Nasdaq
- EQ Nasdaq
- Market Cap
- IINN 25.9M
- EQ 24.8M
- IPO Year
- IINN 2021
- EQ 2018
- Fundamental
- Price
- IINN $1.06
- EQ $0.64
- Analyst Decision
- IINN
- EQ Buy
- Analyst Count
- IINN 0
- EQ 2
- Target Price
- IINN N/A
- EQ $5.00
- AVG Volume (30 Days)
- IINN 1.8M
- EQ 141.5K
- Earning Date
- IINN 08-15-2024
- EQ 11-13-2024
- Dividend Yield
- IINN N/A
- EQ N/A
- EPS Growth
- IINN N/A
- EQ N/A
- EPS
- IINN N/A
- EQ N/A
- Revenue
- IINN N/A
- EQ $45,914,000.00
- Revenue This Year
- IINN N/A
- EQ $4.76
- Revenue Next Year
- IINN N/A
- EQ N/A
- P/E Ratio
- IINN N/A
- EQ N/A
- Revenue Growth
- IINN N/A
- EQ 7.70
- 52 Week Low
- IINN $0.80
- EQ $0.56
- 52 Week High
- IINN $2.45
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- IINN 46.38
- EQ 39.10
- Support Level
- IINN $1.00
- EQ $0.64
- Resistance Level
- IINN $1.11
- EQ $0.73
- Average True Range (ATR)
- IINN 0.11
- EQ 0.08
- MACD
- IINN 0.01
- EQ -0.00
- Stochastic Oscillator
- IINN 67.27
- EQ 10.12
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.